Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
about
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to dateAdaptation to antiangiogenic therapy in neurological tumorsAdvances in epigenetic glioblastoma therapy.Recurrent malignant gliomas.Antiangiogenic therapy for glioblastoma: current status and future prospects.Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewBevacizumab for glioblastoma: current indications, surgical implications, and future directionsDosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.Predictive biomarkers investigated in glioblastoma.Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.Incorporation of biomarkers in phase II studies of recurrent glioblastoma.Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.Bevacizumab in recurrent glioblastoma: five informative patient scenarios.Novel chemotherapeutics and other therapies for treating high-grade glioma.Glioblastoma targeted therapy: updated approaches from recent biological insights.Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.Investigational new drugs for brain cancer.Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment.Bevacizumab in recurrent glioblastoma: open issues.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.Reoperation for Recurrent Glioblastoma and Its Association With Survival Benefit.Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.Multiparametric MRI as an early biomarker of individual therapy effects during concomitant treatment of brain tumours.Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.Trends in Malignant Glioma Monoclonal Antibody Therapy.
P2860
Q26822717-EE309610-1586-4F2C-9649-A3C376695EFDQ28082908-E2BCE3B0-2673-4071-B405-3B5A874FC49BQ33567030-498181AC-7162-4A53-8926-80B6E1FAC9FEQ34438507-F62F2FF9-EC4C-44BF-9E8A-AA184E897F02Q34523319-811BF9D3-CD1D-41CB-9DEB-5103378B9562Q35771783-08687D15-B7CF-4DAE-83C0-08A861567B27Q35793888-3C426750-3800-4528-AAB3-D538B7CDC2EAQ35796826-00BD5760-EEAD-4F18-8285-99D895998222Q35895174-23B37C72-C3A7-4A89-9B6B-7DE4004DCF73Q36270115-29BED31E-F564-44AB-9B36-EBE609C15F70Q36822207-5132C1DE-97FA-4541-8CC7-35DD993B606AQ36998239-52014988-E4ED-4594-B4FB-0F04D1884B75Q38237337-A71926B7-123A-4478-9107-8350E06F63F5Q38255001-8B129A42-6A92-46CD-9EB2-E4C5B142CDFBQ38298124-371A1FF9-A72E-4BA2-9805-49E52D0ADA35Q38307997-03A69518-013A-4112-A0A9-70871F4F0A64Q38409696-EA1F5014-8CA3-44C8-B437-BAAB0AF20C80Q38569802-A2625892-0C16-42E3-9341-BFE913E40094Q38597700-6E59C337-F1EA-4C7A-A214-86872F33127AQ38672966-F3BF3C26-8247-4992-B749-40D57C5F6056Q38676891-95F715B3-F6F3-47A6-890B-41AF50FA8953Q38786782-63190189-887A-4175-96A7-7DB827C42F09Q38832510-EE0109C2-789E-48E5-B1E3-FD6E412E9CB3Q38838030-7730301F-196C-4027-A58A-9972656ECD59Q38965301-BFCBD70D-4567-467F-8C80-3B43A6464CEDQ39022941-8010494F-8164-40D7-8671-EEF99B5E0030Q39436924-3FF3D4EC-4FB3-4AD4-8224-1E133D45E9DEQ39607166-6941039A-C0AB-4486-8D82-0B8621357EF7Q41431404-EF8F590B-36ED-4735-BD80-19351D79E0CBQ47553864-5A0CB2A7-140D-4D10-8CDB-F8CBEB461453Q47903338-A016BE76-0843-4B4A-A497-C55A9EB02AC1Q49066603-B3E57C9C-BA4B-4233-AE19-803E112E7FFFQ49501093-2BD3AE77-5AE8-45A4-BDCE-1AD988BBC5E0Q52570231-CF2236C3-BFBC-4EAD-B02D-06092D5C686FQ52654231-FB23DC15-8708-4FE2-9A85-EE1EDD2AC3E8Q53829611-15D45EF4-4343-4281-8691-453FA213D962Q54313994-0985C151-89EE-4CE3-926B-4F7EB576A4D8Q54942652-5B846FCE-2849-41B5-836B-A1E1BF921011
P2860
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of bevacizumab ...... cancer treatment group trial.
@en
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma
@nl
type
label
Phase II study of bevacizumab ...... cancer treatment group trial.
@en
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma
@nl
prefLabel
Phase II study of bevacizumab ...... cancer treatment group trial.
@en
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma
@nl
P2093
P2860
P1476
Phase II study of bevacizumab ...... cancer treatment group trial.
@en
P2093
Caterina Giannini
Donald W Northfelt
Jackie M Lafky
Jan C Buckner
Joon H Uhm
Kurt A Jaeckle
Patrick J Flynn
S Keith Anderson
Shaji K Kumar
Teresa K Kimlinger
P2860
P304
P356
10.1158/1078-0432.CCR-13-0708
P407
P577
2013-07-05T00:00:00Z